Ixchiq (Chikungunya vaccine (live))
PRIMEAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- Chikungunya vaccine (live)
- Company
- Valneva Austria GmbH
- Status
- Authorised
- Therapeutic area
- Chikungunya virus
- CHMP opinion
- Thu 30 May 2024
- EU approval
- Fri 28 Jun 2024
- Designations
- PRIME, Additional monitoring
- Application
- EMEA/H/C/005797
- ATC
- J07BP01
- Official record
- www.ema.europa.eu
Indication
Ixchiq is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older at high risk of acquiring chikungunya infection. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
Tue 14 Jul 2026🇪🇺 DHPC safety letter
Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated): DHPC sent to healthcare professionals
Adverse event, Restriction of indication; Chikungunya virus · source
Follow Ixchiq
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.